COX-2 inhibitors in cancer prevention;Inhibidores de la ciclooxigenasa-2 en la prevención del cáncer

Revista Clinica Espanola

Volumn 205, Issue 9, 2005, Pages 446-456

  Grau de Castro, J J ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Cancer prevention; Chemoprevention; COX 2; COX 2 inhibitor; Cyclooxygenase 2

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; ACETYLSALICYLIC ACID; ANTIINFLAMMATORY AGENT; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETODOLAC; MELOXICAM; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NIMESULIDE; PROSTAGLANDIN SYNTHASE; ROFECOXIB; SULINDAC; TAMOXIFEN;

ACTINIC KERATOSIS; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER; CANCER PREVENTION; CANCER RESEARCH; CHEMOPROPHYLAXIS; DRUG MECHANISM; ENZYME INHIBITION; FAMILIAL POLYPOSIS; HUMAN; NONHUMAN; REVIEW; SKIN CANCER; SQUAMOUS CELL CARCINOMA;

EID: 27744543533     PISSN: 00142565     EISSN: None     Source Type: Journal    
DOI: 10.1157/13079075     Document Type: Review

References (122)

1. Koki AT, Leahy KM, Masferrer JL. Potential utility of COX-2 inhibitors in chemoprevention and chemotherapy. Exp Opin Invest Drugs. 1999;8: 1623-38.
2. Danemberg AJ, Altorki NK, Boyle JO, Dang C, Howe LR, Wek Sler BB, et al. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol. 2001; 2:544-51.
3. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflamatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst. 2002;94:252-66.
4. Vainio H. Is COX-2 inhibition a panacea for cancer prevention? Int J Cancer. 2001;94:613-4.
5. Picó Navarro C, Bosch José X. Quimioprevención del cáncer de mama. Rev Cancer (Madrid). 2002;16:138-53.
6. Altisent R, Brotons C, González R, Serrat D, Judez J, Gracia D. Ética de la actividad preventiva en Atención Primaria. Med Clin (Barc). 2001;117:740-50.
7. Bennett A, Charlier EM, McDonald AM, Simpson JS, Stamford IF, Zebro T. Prostaglandins and breast cancer. Lancet. 1977;2:624-6.
8. Hansen-Petrik MB, McEntee MF, Jonhson BT, Obukowicz MG, Masferrer J, Zweijel B, et al. Selective inhibition of Δ-6 desaturase impedes intestinal tumorigenesis. Cancer Letters. 2002; 175:157-63.
9. Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, et al. Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem. 2001; 276;18563-9.
10. Vadlamudi R, Mandal M, Adam L, Steinbach G, Mendelsohn J, Kumar R. Regulation of cyclooxygenase-2 pathway by HER2 receptor. Oncogene. 1999;18:305-14.
11. Subbaramaiah K, Norton L, Gerald W, Dannenberg AJ. Cyclooxygenase-2 is overexpressed in HER-2/neu-positive breast cancer. Evidence for involvement of AP-1 and PEA3. J Biol Chem. 2002;277:18649-57.
12. Howe LR, Subbaramaiah K, Patel J, Masferrer JL, Deora A, Hudis C, et al. Celecoxib, a selective Cyclooxygenase 2 inhibitor, protects against human epidermal factor receptor 2 (HER-2)/neu-induced breast cancer. Cancer Res. 2002;62:5405-7.
13. Hao X, Bishop AE, Wallace M, Wang H, Willcocks TC, Maclouf J, et al. Early expression of cyclo-oxigenase-2 during sporadic colorectal carcinogenesis. J Pathol. 1999;187:295-301.
14. Kucherlapati R, Lin DP, Edelmann W. Mouse models for human familial adenomatous polyposis. Semmin Cancer Biol. 2001;11:219-25.
15. Sonoshita M, Takaku K, Oshima M, Sugihara K, Taketo MM, et al. Cyclooxygenase-2 expression in fibroblasts and endothelial cells of intestinal polyps. Cancer Res. 2002; 62:6846-9.
16. Sunayama K, Konno H, Nakamura T, Kashiwabara H, Shoji T, Tsuneyoshi T, et al. The role of Cyclooxygenase-2 in two different morphological stages of intestinal polyps in APC D474 knockout mice. Carcinogenesis. 2002;23:1351-9.
17. Müller-Decker K, Neufang G, Berger I, Neumann M, Marks F, Furstenberger G. Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis. Proc Natl Acad Sci. 2002;99:12483-8.
18. Fisher SM, Lo HH, Gordon GB, Seibert K, Kelloff G, Lubet RA, et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, and indomethacin against ultraviolet light-induced skin carcinogenesis. Mol Carcinog. 1999;25:231-40.
19. Reddy BS, Hirose Y, Lubet R, Steal V, Kelloff G, Paulson S, et al. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res. 2000;60:293-7.
20. Brown WA, Skinner SA, Malcontenti-Wilson C, Vogiagis D, O'Brien PE. Non-steroidal anti-inflamatory drugs with activity against either cyclooxygenase 1 or cyclooxygenase 2 inhibit colorectal cancer in a model by inducing apoptosis and inhibiting cell proliferation. Gut. 2001;48:660-6.
21. Yoshimatsu K, Golijanin D, Paty PB, Soslow RA, Jakobsson PJ, Delellis Ra, et al. Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer. Clin Cancer Res. 2001;7: 3971-6.
22. Zweifel BS, Davis TW, Ornberg RL, Masferrer JL. Direct evidence for a role of cyclooxygenase, 2-derived Prostaglandin E2 in human head and neck Xenograft tumors. Cancer Res. 2002;62:6706-11.
23. Min/+ mice. Cancer Res. 2002;62:403-8.
24. Bhattacharya M, Peri KG, Almazan G, Ribeiro-da-Silva A, Sichi H, Durocher Y, et al. Nuclear localization of prostaglandin E2 receptors. Proc Natl Acad Sci. 1998;95:15792-7.
25. Chan TA, Morin PJ, Vogelstein B, Kinzler KW. Mechanisms underlying nonsteroidal antiinflamatory drug-mediated apoptosis. Proc Natl Acad Sci. 1998;95:681-6.
26. Kim SH, Song SH, Kim SG, Chun KS, Lim SY, Nahk, et al. Celecoxib induces apoptosis in cervical cancer cells independent of cyclooxygenase using NF-(B as a possible target. J Cancer Res Clin Oncol. 2004;130:551-60.
27. Gisbert JP, Pajares JM. Ciclooxigenasa 2 (COX-2), Helicobacter pylori y cáncer gástrico. Med Clin (Barc). 2003;120:189-93
28. Correa P, Fontham ETH, Bravo JC, Bravo LE, Ruiz B, Zarama G, et al. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements an anti-Helicobacter pylori therapy. J Natl Cancer Inst. 2000;92:1881-8.
29. El-Omar EM, Carrington M, Chow WH, McColl KE, Bream JK, Young HA, et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature. 2000;404:398-402.
30. Schäfer G, Cramer T, Suske G, Kemmer W, Wiedennmann B, Hocker M, et al. Oxidative stress regulates vascular endothelial growth factor-A gene transcription through Sp-1 and Sp3-dependent activation of two proximal GC-rich promoter elements. J Biol Chem. 2003; 278:8190-8.
31. Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nature Rev Cancer. 2003;3:276-85.
32. Wang JM, Deng X, Gong W, Su S. Chemokines and their role in tumor growth and metastasis. J Immunol Meth. 1998;220:1-17.
33. Coussens LM, Werb Z. Inflamation and cancer. Nature. 2002;420: 860-7.
34. Dvorak HF. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 1986;315:1650-9.
35. Tanabe T, Tohnai N. Cyclooxygenase isozymes and their gene structures and expression. Prostaglan & other Lipid Mediators. 2002;68-9:95-114.
36. Jang, BC, Hla T. Regulation of expression and potential carcinogenic role of cyclooxygenase-2. En: Harris RE, editor. COX-2 blockade in cancer prevention and therapy. Totowa, New Jersey: Humana Press Inc, 2003. p. 171-84.
37. Kanekura T, Higashi Y, Kanzaki T. Inhibitory effects of 9-cis-retinoic acid and pyrrolidinedithiocarbamate on cyclooxygenase (COX)-2 expression and cell growth in human skin squamous carcinoma cells. Cancer Letters. 2000;161:177-83.
38. Fujita J, Mestre JR, Zeldis JB, Subbaramaiah K, Dannenberg AJ, et al. Thalidomide and its analogues inhibit lipopolysaccharide-mediated induction of cyclooxygenase-2. Clin Cancer Res. 2001;7:3349-55.
39. Chen Z, Zhang X, Li M, Wang Z, Wieand HS, Grandis JR, et al. Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck. Clin Cancer Res. 2004:10:5930-39.
40. Llor X, Pons E, Roca A, Álvarez M, Mane J, Fernández-Banares F, et al. The effects of fish oil, olive oil, oleic acid and linoleic acid on colorectal neoplastic processes. Clin Nutrition. 2003; 22:71-9.
41. Cao Y, Prescott SM. Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol. 2002;190:279-86.
42. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000; 100:57-70.
43. Hahn WC, Weinberg RA. Rules for making human tumor cells. N Eng J Med. 2002;347:1593-603.
44. Mohammed SI, Bennett PF, Craig BA, Glickman NW, Mustaers AJ, Snyder PW, et al. Effects of the cyclooxygenase inhibitor, Piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res. 2002;62:356-8.
45. Hida T, Kozaki K, Ito H, Miyaishi O, Tatamatsu Y, Suzuki T. Significant growth inhibition of human lung cancer cells both in vitro and in vivo by the combined use of a selective cyclooxygenase 2 inhibitor, JTE-522, and conventional anticancer agents. Clin Cancer Res. 2002;8:2443-47.
46. Yao, M, Kargman S, Lam EC, Kelly CR, Zheng Y, Luk P, et al. Inhibition of cyclooxygenase-2 by rofecoxib attenuates the growth and metastatic potential of colorectal carcinoma in mice. Cancer Res. 2003;63:586-92.
47. Masferrer JL, Leahy KM, Koki AT, Zweifel BS, Settle SL, Woerner BM, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 2000;60:1306-11.
48. Martin C, Connelly A, Keku TO, Mountcastle SB, Galanko J, Woosley JT, et al. Nonsteroidal anti-inflamatory drugs, apoptosis, and colorectal adenomas. Gastroenterol. 2002;123:1770-7.
49. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM, Chen CS. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem. 2000;275:11397-403.
50. Johnson AJ, Song X, Hsu AL, Chen C. Apoptosis signaling pathways mediated by Cyclooxygenase-2 inhibitors in prostate cancer cells. Advan Enzyme Regul. 2001;41:221-35.
51. Patti R, Gumired K, Reddana P, Sutton LN, Philips PC, Reddy CD, et al. Overexpression of cyclooxygenase-2 (COX-2) in human primitive neuroectodermal tumors: effect of celecoxib and rofecoxib. Cancer Letters. 2002;180:13-21.
52. Waskewitch C, Blumenthal RD, Li H, Stein R, Goldenberg DM, Buxton J. Celecoxib exhibits the greatest potency amongst cyclooxygenase (COX) inhibitors for growth inhibition of COX-2-negative hematopoietic and epithelial cell lines. Cancer Res. 2002;62:2029-33.
53. Tsujii M, DuBois R. Alteration in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoside synthase 2. Cell. 1995; 83:493-501.
54. Kundu N, Fulton AM. Selective cyclooxygenase (COX)-1 or COX-2 inhibitors control metastatic disease in a murine model of breast cancer. Cancer Res. 2002;62:2343-6.
55. Connolly EM, Harmey JH, O'Grady T, Foley D, Roche-Nagle G, Kay E, et al. Cyclo-oxygenase inhibition reduces tumor growth and metastasis in an orthotopic model of breast cancer. Br J Cancer. 2002;87:231-7.
56. Kakiuchi Y, Tsujii S, Tsujii M, Murata H, Kawai N, Yasumaru M, et al. Cyclooxygenase-2 activity altered the cell-surface carbohydrate antigens on colon cancer cells and enhanced liver metastasis. Cancer Res. 2002;62:1567-72.
57. Jones MK, Wang H, Peskar B, Levin E, Itani RM, Sarkej IJ, et al. Inhibition of angiogenesis by nonsteroidal anti-inflamatory drugs: insight into mechanisms and implications for cancer growth an ulcer healing. Nature Med. 1999;5:1418-23.
58. Habib A, Creminon C, Frobert Y, Grassy J, Pradelles P, Maclouj J. Demonstration of an inducible cyclooxygenase in human endothelial cells using antibodies raised against the carboxyl-terminal region of the cyclooxygenase-2. J Biol Chem 1993; 268:23448-54.
59. Matsumoto H, Ma W, Daikoku T, Zhao X, Paria BC, Das SK, et al. Cyclooxygenase-2 differentially directs uterine angiogenesis during implantation in mice. J Biol Chem. 2002;277:29260-7.
60. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998;93:705-16.
61. Leahy KM, Koki AT, Masferrer JL. Role of cyclooxygenases in angiogenesis. Current Med Chem. 2000;7:1163-70.
62. Amano H, Hayashi I, Endo H, Kitasolo H, Yamashina S, Maruyama T, et al. Host prostaglandin E2-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J Exp Med. 2003;197:221-32.
63. Williams CS, Tsujii M, Reese J, Dey SK, DuBois RN. Host cyclooxygenase-2 modulates carcinoma growth. J Clin Invest 2000;105:1589-94.
64. Leahy KM, Ornberg RL, Wang Y, Zweijel BS, Koki AT, Masferrer SL, et al. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res. 2002; 62:625-31.
65. Majima M, Hayashi I, Muramatsu M, Katada J, Yamashima S, Katori M. Ciclo-oxygenase-2 enhances basic fibroblast growth factor-induced angiogenesis through induction of vascular endothelial growth factor in rat sponge implants. Br J Pharmacol. 2000;130:641-9.
66. Konerding MA, Fait E, Gaumann A. 3D microvascular architecture of pre-cancerous lesions and invasive carcinomas of the colon. Br J Cancer. 2001;84:1354-62.
67. Tamura M, Sebastian S, Gurates B, Yang S, Fang Z, Bulun SE. Vascular endothelial growth factor up-regulates cyclooxygenase-2 expression in human endothelial cells. J Clin Endoc Metab. 2002;87:3504-7.
68. Williams CS, Watson AJM, Sheng H, Helan R, Shao J, DuBois RN. Celecoxib prevents tumor growth in Vivo without toxicity to normal gut: lack of correlation between in vitro and in vivo models. Cancer Res. 2000;60:6045-51.
69. Hayashi Y, Kobayshi M, Kuwata H, Atsumi G, Deguchi K, Feng Wei X, et al. Interferon-g and interleukin 4 inhibit interleukin 1b-induced delayed prostaglandin E2 generation throughout suppression of cyclooxigenase-2 expression in human fibroblasts. Cytokine. 2000;12:603-12.
70. Barbera-Guillén E, Nyhus JK, Wolford CC, Friece CR, Sampsel JW. Vascular endothelial growth factor secretion by tumor-infiltrating macrofagues essentially supports tumor angiogenesis, and IgG immune complexes potentiate the process. Cancer Res. 2002;62:7042-9.
71. Barbera-Guillén E, May KF, Nyhus JK, Nelson MB. Promotion of tumor invasion by cooperation of granulocytes and macrophages activated by antitumor antibodies. Neoplasia. 1999;1:453-60.
72. Chen JJW, Yao PL, Yuan A, Hong TM, Shun CT, Kuo ML, et al. Upregulation of tumor interleukin-8 expression by infiltrating macrophagages: its correlation with tumor angiogenesis and patient survival in non-small cell lung cancer. Clin Can Res. 2003;9:729-37.
73. Davies G, Martín LA, Sacks N, Dowsett M. Cyclooxygenase-2 (COX-2), aromatase and breast cancer: a possible role for COX-2 inhibitors in breast cancer Chemoprevention. Ann Oncol. 2002;13:669-78.
74. Ogawa H, Nishihira J, Sato Y, Kondo M, Takahashi N, Oshima T, et al. An antibody for macrophage migration inhibitory factor suppresses tumor growth and inhibits tumor-associated angiogenesis. Cytokine. 2000;12:309-14.
75. Ueno T, Toi M, Saji H, Muta M, Bando H, Kuroi K, et al. Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res. 2000;6:3282-9.
76. Iñiguez MA, Punzón C, Fresno M. Induction of cyclooxygense-2 on activated T lymphocytes: regulation of T Cell activation by cyclooxygenase-2 inhibitors. J Immunol. 1999;163:111-9.
77. Stolina M, Sharma S, Lin Y, Dohadwala M, Gardner B, Luo J, et al. Specific inhibition of cyclooxygenase-2 restores antitumor reactivity by altering the balance of OL-10 and IL-12 synthesis. J Immunol. 2000;164:361-70.
78. Harizi H, Juzan M, Pitard V, Moreau JF, Gualde N. Cyclooxygenase-2-issued prostaglandin E2 enhances the production of endogenous IL-10, wich down-regulates dendritic cell functions. J Immunol. 2002;168:2255-63.
79. Sharma S, Stolina M, Yang SC, Baratelli F, Lin JF, Alianzar K, et al. Tumor cyclooxygenase 2-dependent suppression of dendritic cell function. Clin Cancer Res. 2003; 9:961-8.
80. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Breasalier R, et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003;348:891-9.
81. Sandler RS, Halabi S, Baron JA, Budinger S, Paskett E, Keresztes R, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med. 2003; 348: 883-90.
82. Giardello FM, Hamilton SR, Krush AJ, Piantadosi S, Hylind LM, Celano P, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med. 1993;328:1313-6.
83. Steinbach G, Linch PM, Phillips RKS, Wallace MH, Hawk E, Gordon GB, et al. The effect of celecoxib, a cycloxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med. 2000;342:1946-52.
84. Phillips RKS, Wallace MH, Linch PM, Hawk E, Gordon GB, Saunders BP, et al. A randon-dzed, double blind, placebo controlled study of Celecoxib, a selective cycloxigenase-2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut. 2002;50:857-60.
85. Khuder SA, Mutgi AB. Breast cancer and NSAID use: a meta-analysis. Br J Cancer. 2001;84:1188-92.
86. Muscat JE, Chen SQ, Richie JP, Altorki NK, Citron M, Olson S, et al. Risk of lung carcinoma among users of nonsteroidal antiinflamatory drugs. Cancer 2003;97:1732-6.
87. Castelao JE, Yuan JM, Gago-Domínguez M, Yu MC, Ross RK. Non-steroidal anti-inflamatory drugs and bladder cancer prevention. Br J Cancer. 2000; 82:1364-9.
88. Bosseti C, Talamini R, Francheschi S, Negri E, Garavello W, La Vecchia C, et al. Aspirin use and cancer of the upper aerodigestive tract. Br J Cancer. 2003;88:672-4.
89. Anderson KE, Johnson TW, Lazovich DA, Folsom AR, et al. Association between nonsteroidal anti-inflamatory drug use and the incidence of pancreatic cancer. J Natl Cancer Inst. 2002;94:1168-71.
90. Terry MB, Gammon MD, Shang FF, Tawfik H, Teitelbaum SL, Britton JA, et al. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA. 2004;291:2433-9.
91. García-Rodríguez LA, González-Pérez A. Risk of breast cancer among users of aspirin and other anti-inflammatory drugs. Brit J Cancer. 2004;91:525-9.
92. García-Rodríguez LA, González-Pérez A. Inverse association between nonsteroidal anti-inflammatory drugs and prostate cancer. Cancer Epidemiol Biomarkers & Prev. 2004;13:649-53.
93. Altorki NK, Keresztes RS, Port JL, Libby DM, Korst RJ, Hieder BD, et al. Celecoxib, a selective cyclo-oxigenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer. J Clin Oncol. 2003;21:2645-50.
94. Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J, et al. COX-2 is expressed in human pulmonary, colonic, and mammary tumors. Cancer 2000;89:2637-45.
95. Chang BW, Kim DH, Kowalski DP, Burleson JA, Son YH, Wilson LD, et al. Prognostic significance of cyclooxygenase-2 in oropharyngeal squamous cell carcinoma. Clin Cancer Res. 2004;10:1678-84.
96. Ristimäki A, Sivula A, Lundin J, Lundin M, Salminen T, Haglund C, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res 2002; 62:632-5.
97. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the US. Preventive Services Task Force. Ann Intern Med. 2002;136:161-72.
98. Leese PT, Hubbard RC, Karim A, Isakson PC, Yu SS, Geis GS. Effects of celecoxib, a novel cyclooxygenase-2 inhibitor, on platelet function in healthy adults: a randomized, controlled trial. J Clin Pharmacol. 2000;40: 124-32.
99. Lanas A. Impacto económico de los efectos secundarios gastrointestinales asociados a antiinflamatorios no esteroideos en el Servicio Nacional de Salud. Med Clin (Barc). 2000;114 Supl 3:46-53.
100. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of Rofecoxib and Naproxen in patients with rheumatoid artritis. N Engl J Med. 2000;343:1520-8.
101. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonesteroidal anti-inflamatorydrugs for osteoarthritis and reumathoid arthritis: the CLASS study: a randomized study. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284:1247-55.
102. Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthitis: systematic review of randomised controlled trials. Br Med J. 2002;325:619-23.
103. Masferrer JL, Needleman P. Anti-inflamatories for cardiovascular disease. Proc Natl Acad Sci USA. 2000;97:12400-1.
104. Mamdani M, Juurlink DN, Lee DS, Rochon PA, Kopp A, Naglie G, et al. Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet. 2004;363:1751-6.
105. Solomon DH, Scneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, et al. Relationship between selective cyclooxygenase inhibitors and acute myocardial infarction in older adults. Circulation. 2004;109:2068-73.
106. Miller BE, Cappllari JO. Cyclooxigenase-2 inhibition for the treatment of cervical intraepithelial neoplasia [abstract 381]. Proceed Am Soc Clin Oncol. 2003;22:95.
107. Ricchi P, Zarrilli R, di Palma A, Acquaviva AM. Nonsteroidal anti-inflamatory drugs in colorectal cancer: from prevention to therapy. Br J Cancer. 2003; 88:803-7.
108. Winerhalter RC, Hirsch FR, Kotantoulas GK, Franklin WA, Bunn PA. Chemoprevention of lung cancer-from biology to clinical reality. Ann Oncol 2004;15:185-96.
109. Komaki R, Liao Z, Milas L. Improvement strategies for molecular targeting: Cyclooxygenase-2 inhibitors as radiosensitizers for non-small lung cancer. Sem Oncol. 2004; Suppl 1:47-53.
110. Klein EA, Thompson MI. Update on chemoprevention of prostate cancer. Curr Opin Urol. 2004;14:143-9.
111. Simone AM, Li YJ, Broemeling LD, Johnson MM, Tuna M, Tari A. Cyclooxygenase-2 is essential for HER/neu to suppress N-(hydroxyphenyl) retinamide apoptotic effects in breast cancer cells. Cancer Res. 2004;64: 1224-8.
112. Wang D, Dubois RN. Cyclooxygenase-2: a potential target in breast cancer. Semin Oncol. 2004;1 Suppl 3:64-73.
113. Benoit V, Relic B, Leval X, Chariot A, Merville MP, Bours V. Regulation of HER-2 oncogene expression by cyclooxygenase-2 and prostaglandin E2. Oncogene. 2004;23: 1631-5.
114. Gasparini G, Longo L, Sarmiento R, Morabito A. Inhibitors of cyclooxygenase 2: a new class of anticancer agents? Lancet Oncol 2003;4: 605-15.
115. Grau JJ, Carles J, Monzo M, et al. Expression of cyclooxygenase-2 mRNA (COX2-mRNA) in peripheral blood of head and neck cancer patients and healthy controls [abstract]. Proc ASCO. 2004;23:2061.
116. Pruthi RS, Derksen JE, Moore D. A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. BJU Int. 2004;3:275-8.
117. Choi H, Milas L. Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rationale advance? J Natl Cancer Inst. 2003;95: 1440-52.
118. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352:1092-102.
119. Solomon SD, McMurray JJV, Pfeffer MA, Wittes J, Fowler R, Anderson WF, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352:1071-80.
120. Nussmeier NA, Whelton AA, Brown MT, Langford RM, Hoeft A, Parlow JL, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med. 2005;352:1081-91.
121. Psaty BM, Furberg CD. COX-2 inhibitors-lessons in drug safety. N Engl J Med. 2005;352:1133-4.
122. Okie S. Raising the safety bar - The FDA's Coxib Meeting. N Engl J Med. 2005;352:1283-5.